Concepts (189)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Luminescent Agents | 7 | 2021 | 11 | 1.980 |
Why?
|
Luciferases | 10 | 2022 | 105 | 1.670 |
Why?
|
Luminescent Measurements | 9 | 2020 | 58 | 1.550 |
Why?
|
Firefly Luciferin | 3 | 2020 | 5 | 1.050 |
Why?
|
Pyrazines | 3 | 2021 | 46 | 0.830 |
Why?
|
Proteomics | 2 | 2021 | 246 | 0.790 |
Why?
|
Imidazoles | 3 | 2021 | 175 | 0.790 |
Why?
|
Diazomethane | 1 | 2021 | 2 | 0.770 |
Why?
|
Affinity Labels | 1 | 2021 | 66 | 0.760 |
Why?
|
Azides | 1 | 2021 | 56 | 0.760 |
Why?
|
Hydrocarbons, Chlorinated | 1 | 2021 | 25 | 0.750 |
Why?
|
Cross-Linking Reagents | 1 | 2021 | 80 | 0.750 |
Why?
|
Bioluminescence Resonance Energy Transfer Techniques | 3 | 2021 | 8 | 0.570 |
Why?
|
Luciferases, Firefly | 3 | 2020 | 5 | 0.480 |
Why?
|
Epoxide Hydrolases | 3 | 2008 | 8 | 0.480 |
Why?
|
HEK293 Cells | 12 | 2021 | 326 | 0.460 |
Why?
|
Luminescence | 4 | 2020 | 31 | 0.430 |
Why?
|
Furans | 3 | 2021 | 27 | 0.410 |
Why?
|
Luminescent Proteins | 2 | 2020 | 57 | 0.370 |
Why?
|
Fluorescent Dyes | 3 | 2019 | 191 | 0.360 |
Why?
|
Coleoptera | 2 | 2020 | 8 | 0.340 |
Why?
|
Adenosine Triphosphate | 2 | 2020 | 314 | 0.310 |
Why?
|
Substrate Specificity | 4 | 2020 | 234 | 0.300 |
Why?
|
Indicators and Reagents | 3 | 2022 | 63 | 0.290 |
Why?
|
Alkanes | 2 | 2016 | 10 | 0.270 |
Why?
|
Histone Deacetylases | 2 | 2021 | 99 | 0.270 |
Why?
|
Molecular Structure | 4 | 2017 | 397 | 0.260 |
Why?
|
Protein Interaction Maps | 2 | 2015 | 30 | 0.260 |
Why?
|
Protein Interaction Mapping | 2 | 2015 | 62 | 0.260 |
Why?
|
Glutamic Acid | 1 | 2008 | 332 | 0.250 |
Why?
|
Binding, Competitive | 2 | 2021 | 165 | 0.240 |
Why?
|
Optical Imaging | 2 | 2021 | 46 | 0.230 |
Why?
|
Chromatography, Liquid | 2 | 2021 | 120 | 0.220 |
Why?
|
Mass Spectrometry | 2 | 2021 | 284 | 0.210 |
Why?
|
Benzothiazoles | 2 | 2019 | 14 | 0.200 |
Why?
|
Antibodies | 1 | 2022 | 241 | 0.200 |
Why?
|
Peptides | 2 | 2022 | 455 | 0.200 |
Why?
|
Immunologic Tests | 1 | 2021 | 9 | 0.190 |
Why?
|
Receptors, Adrenergic, alpha-2 | 1 | 2021 | 17 | 0.190 |
Why?
|
K562 Cells | 1 | 2021 | 44 | 0.190 |
Why?
|
Dasatinib | 1 | 2021 | 17 | 0.190 |
Why?
|
Alkylation | 1 | 2020 | 26 | 0.190 |
Why?
|
Hydrolases | 1 | 2021 | 20 | 0.190 |
Why?
|
Drug Discovery | 3 | 2021 | 94 | 0.190 |
Why?
|
Propranolol | 1 | 2021 | 102 | 0.190 |
Why?
|
Retinal Vessels | 1 | 2021 | 74 | 0.180 |
Why?
|
Mice, Nude | 5 | 2021 | 294 | 0.180 |
Why?
|
Virus Diseases | 1 | 2020 | 31 | 0.180 |
Why?
|
Protein Kinases | 1 | 2021 | 122 | 0.180 |
Why?
|
Ultraviolet Rays | 1 | 2021 | 130 | 0.180 |
Why?
|
Receptors, Adrenergic, beta-2 | 1 | 2020 | 34 | 0.180 |
Why?
|
Histone Deacetylase Inhibitors | 3 | 2015 | 116 | 0.180 |
Why?
|
Receptors, G-Protein-Coupled | 1 | 2021 | 167 | 0.170 |
Why?
|
Machine Learning | 1 | 2021 | 170 | 0.170 |
Why?
|
Antibodies, Blocking | 1 | 2019 | 17 | 0.170 |
Why?
|
Diagnostic Imaging | 1 | 2021 | 201 | 0.170 |
Why?
|
Structure-Activity Relationship | 4 | 2021 | 420 | 0.170 |
Why?
|
Temperature | 1 | 2020 | 340 | 0.170 |
Why?
|
Fluorescence Resonance Energy Transfer | 2 | 2015 | 45 | 0.160 |
Why?
|
Cell Membrane | 1 | 2020 | 524 | 0.160 |
Why?
|
Insect Proteins | 1 | 2018 | 4 | 0.160 |
Why?
|
Phosphotransferases | 1 | 2017 | 16 | 0.150 |
Why?
|
Humans | 22 | 2022 | 68549 | 0.150 |
Why?
|
Peptide Fragments | 1 | 2020 | 483 | 0.150 |
Why?
|
Enzyme Assays | 2 | 2020 | 5 | 0.150 |
Why?
|
Ligands | 4 | 2021 | 317 | 0.140 |
Why?
|
Palladium | 1 | 2016 | 12 | 0.140 |
Why?
|
Protein Binding | 4 | 2021 | 1027 | 0.130 |
Why?
|
Cells | 1 | 2015 | 7 | 0.130 |
Why?
|
Lung | 1 | 2021 | 849 | 0.130 |
Why?
|
Energy Transfer | 3 | 2021 | 25 | 0.130 |
Why?
|
Chemistry Techniques, Analytical | 1 | 2015 | 8 | 0.130 |
Why?
|
Luciferases, Renilla | 1 | 2015 | 2 | 0.130 |
Why?
|
Mice, Inbred BALB C | 3 | 2021 | 532 | 0.130 |
Why?
|
Enzyme Inhibitors | 2 | 2008 | 659 | 0.130 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 3 | 2022 | 507 | 0.120 |
Why?
|
Protein Kinase Inhibitors | 1 | 2017 | 331 | 0.120 |
Why?
|
Chlorine | 1 | 2015 | 76 | 0.120 |
Why?
|
Pharmaceutical Preparations | 1 | 2015 | 100 | 0.120 |
Why?
|
Inhibitory Concentration 50 | 3 | 2008 | 73 | 0.120 |
Why?
|
Kinetics | 4 | 2020 | 1047 | 0.110 |
Why?
|
Proteins | 1 | 2016 | 473 | 0.110 |
Why?
|
Immunoassay | 2 | 2022 | 64 | 0.100 |
Why?
|
Chemistry, Pharmaceutical | 2 | 2008 | 35 | 0.100 |
Why?
|
Animals | 9 | 2022 | 20880 | 0.100 |
Why?
|
Recombinant Proteins | 3 | 2020 | 742 | 0.100 |
Why?
|
Peptide Hydrolases | 1 | 2011 | 82 | 0.100 |
Why?
|
High-Throughput Screening Assays | 1 | 2011 | 48 | 0.100 |
Why?
|
Models, Molecular | 2 | 2015 | 546 | 0.100 |
Why?
|
HeLa Cells | 3 | 2015 | 237 | 0.100 |
Why?
|
Diamines | 1 | 2008 | 9 | 0.080 |
Why?
|
Hormone Antagonists | 1 | 2008 | 6 | 0.080 |
Why?
|
Drugs, Investigational | 1 | 2008 | 18 | 0.080 |
Why?
|
Receptors, Progesterone | 1 | 2008 | 57 | 0.080 |
Why?
|
Hydrogen Bonding | 1 | 2008 | 66 | 0.080 |
Why?
|
Stereoisomerism | 1 | 2008 | 169 | 0.080 |
Why?
|
Glycine | 1 | 2008 | 89 | 0.080 |
Why?
|
Prostatic Neoplasms | 1 | 1994 | 778 | 0.080 |
Why?
|
Amides | 1 | 2008 | 86 | 0.080 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2008 | 137 | 0.080 |
Why?
|
Crystallography, X-Ray | 1 | 2008 | 190 | 0.080 |
Why?
|
Progesterone | 1 | 2008 | 115 | 0.070 |
Why?
|
Oligopeptides | 2 | 2020 | 152 | 0.070 |
Why?
|
Cytarabine | 1 | 2005 | 44 | 0.060 |
Why?
|
Models, Chemical | 3 | 2011 | 155 | 0.060 |
Why?
|
Carcinoma | 1 | 2005 | 215 | 0.060 |
Why?
|
Ovarian Neoplasms | 1 | 2005 | 267 | 0.060 |
Why?
|
Keratin-18 | 1 | 2022 | 1 | 0.050 |
Why?
|
gamma-Globulins | 1 | 2022 | 8 | 0.050 |
Why?
|
Viral Tropism | 1 | 2022 | 4 | 0.050 |
Why?
|
Melphalan | 1 | 2022 | 15 | 0.050 |
Why?
|
Pancreatic Neoplasms | 1 | 2005 | 332 | 0.050 |
Why?
|
Mice | 3 | 2022 | 8474 | 0.050 |
Why?
|
Lentivirus Infections | 1 | 2021 | 2 | 0.050 |
Why?
|
Solubility | 1 | 2021 | 134 | 0.050 |
Why?
|
Molecular Docking Simulation | 1 | 2021 | 78 | 0.050 |
Why?
|
Photons | 1 | 2020 | 32 | 0.050 |
Why?
|
Injections, Intraperitoneal | 1 | 2020 | 89 | 0.050 |
Why?
|
Oncolytic Viruses | 1 | 2020 | 17 | 0.050 |
Why?
|
Antineoplastic Agents | 1 | 2008 | 1070 | 0.050 |
Why?
|
Spectrometry, Fluorescence | 1 | 2020 | 112 | 0.050 |
Why?
|
Reproducibility of Results | 2 | 2019 | 2077 | 0.050 |
Why?
|
Light | 1 | 2021 | 152 | 0.040 |
Why?
|
Allosteric Regulation | 1 | 2020 | 58 | 0.040 |
Why?
|
Adenoviridae | 1 | 2020 | 295 | 0.040 |
Why?
|
Cetuximab | 1 | 2019 | 19 | 0.040 |
Why?
|
Benzopyrans | 1 | 2019 | 21 | 0.040 |
Why?
|
Transfection | 1 | 2021 | 782 | 0.040 |
Why?
|
Mice, Transgenic | 1 | 2022 | 1033 | 0.040 |
Why?
|
Protein Transport | 1 | 2020 | 280 | 0.040 |
Why?
|
Nitriles | 1 | 2019 | 68 | 0.040 |
Why?
|
Epidermal Growth Factor | 1 | 2019 | 95 | 0.040 |
Why?
|
Biological Availability | 2 | 2008 | 79 | 0.040 |
Why?
|
Indoles | 1 | 2019 | 146 | 0.040 |
Why?
|
Spectroscopy, Near-Infrared | 1 | 2018 | 31 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2019 | 219 | 0.040 |
Why?
|
Cell Proliferation | 2 | 2015 | 1174 | 0.040 |
Why?
|
MCF-7 Cells | 1 | 2018 | 80 | 0.040 |
Why?
|
Drug Design | 2 | 2008 | 107 | 0.040 |
Why?
|
Administration, Oral | 2 | 2008 | 411 | 0.040 |
Why?
|
Microscopy, Fluorescence | 1 | 2018 | 261 | 0.040 |
Why?
|
Catalysis | 1 | 2016 | 123 | 0.030 |
Why?
|
Anti-Inflammatory Agents | 2 | 2008 | 234 | 0.030 |
Why?
|
beta-Arrestin 2 | 1 | 2015 | 29 | 0.030 |
Why?
|
beta-Lactamases | 1 | 2015 | 33 | 0.030 |
Why?
|
beta-Arrestins | 1 | 2015 | 80 | 0.030 |
Why?
|
Histone Deacetylase 1 | 1 | 2015 | 32 | 0.030 |
Why?
|
Cell Line, Tumor | 1 | 2020 | 1851 | 0.030 |
Why?
|
Cyclic AMP-Dependent Protein Kinases | 1 | 2015 | 93 | 0.030 |
Why?
|
Protein Engineering | 1 | 2015 | 35 | 0.030 |
Why?
|
Hydroxamic Acids | 1 | 2015 | 84 | 0.030 |
Why?
|
Arrestins | 1 | 2015 | 92 | 0.030 |
Why?
|
Cell Survival | 1 | 2017 | 901 | 0.030 |
Why?
|
Rectum | 1 | 1994 | 62 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2017 | 1745 | 0.030 |
Why?
|
Amino Acid Sequence | 1 | 2015 | 1082 | 0.030 |
Why?
|
Drug Delivery Systems | 1 | 2015 | 236 | 0.030 |
Why?
|
Male | 4 | 2021 | 37283 | 0.030 |
Why?
|
Molecular Sequence Data | 1 | 2015 | 1446 | 0.030 |
Why?
|
Mutation | 1 | 2018 | 1213 | 0.030 |
Why?
|
Ultrasonography | 1 | 1994 | 453 | 0.030 |
Why?
|
Automation, Laboratory | 1 | 2011 | 5 | 0.020 |
Why?
|
Caseins | 1 | 2011 | 19 | 0.020 |
Why?
|
Sirtuins | 1 | 2011 | 16 | 0.020 |
Why?
|
Mice, Inbred C57BL | 1 | 2018 | 2791 | 0.020 |
Why?
|
Small Molecule Libraries | 1 | 2011 | 53 | 0.020 |
Why?
|
Carcinoma, Transitional Cell | 1 | 1989 | 41 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2011 | 791 | 0.020 |
Why?
|
Urinary Bladder Neoplasms | 1 | 1989 | 138 | 0.020 |
Why?
|
Ethers | 1 | 2008 | 13 | 0.020 |
Why?
|
Benzoic Acid | 1 | 2008 | 5 | 0.020 |
Why?
|
Drug Partial Agonism | 1 | 2008 | 2 | 0.020 |
Why?
|
Leiomyoma | 1 | 2008 | 28 | 0.020 |
Why?
|
Endometriosis | 1 | 2008 | 56 | 0.020 |
Why?
|
Uterine Neoplasms | 1 | 2008 | 99 | 0.020 |
Why?
|
Amines | 1 | 2008 | 98 | 0.020 |
Why?
|
Dogs | 1 | 2008 | 490 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2011 | 1753 | 0.020 |
Why?
|
Female | 3 | 2020 | 38021 | 0.020 |
Why?
|
Transplantation, Heterologous | 1 | 2005 | 122 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2005 | 852 | 0.010 |
Why?
|
Rats | 1 | 2008 | 5300 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 2008 | 1533 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2005 | 2550 | 0.010 |
Why?
|
Karyotyping | 1 | 1989 | 74 | 0.010 |
Why?
|
Flow Cytometry | 1 | 1989 | 489 | 0.010 |
Why?
|
DNA | 1 | 1989 | 597 | 0.000 |
Why?
|
Immunohistochemistry | 1 | 1989 | 1174 | 0.000 |
Why?
|
Adolescent | 1 | 1989 | 8904 | 0.000 |
Why?
|